A "Window Trial" on Boswellia for Breast Cancer Primary Tumors

Inclusion Criteria: * Histologically confirmed ductal carcinoma in situ (DCIS) or invasive breast cancer (stages I, II, or III) with primary tumor(s) ≥ 1.0 cm on mammogram, ultrasound, MRI, or physical exam * 18 years of age or older * Subject must understand risks and benefits of the protocol and be able to give informed consent * Females of child-bearing potential must agree to use an approved form of birth control and to have a negative pregnancy test result before and throughout the study * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate hematologic and end organ function * Ability and capacity to comply with the study and follow-up procedure * Subjects must be scheduled for surgery at MUSC no less than 5 days from the planned start of day 1 and no more than 56 days from the planned start of day 1. * At least 6 sections of unstained slides should be obtained. If sufficient slides or tissue is unavailable, the patient will be excluded from the trial. Exclusion Criteria: * Subjects undergoing neoadjuvant chemotherapy or neoadjuvant endocrine therapy * Subjects with end-stage kidney disease and/or grade II liver dysfunction * Subject has active or history of deep vein thrombosis (DVT) * Subject has a history of coagulopathies or hematological disorders * Subjects who are pregnant or are lactating. * Subjects already taking drugs known to be 5-lipoxygenase inhibitors (Refer to section 5) * Subjects taking drugs that interact with OATP1B3 (an anion transporter), MRP2 (a multidrug resistant protein), and/or P-Glycoprotein (P-Gp) (Refer to section 5.) * Subjects taking anti-coagulants or platelet inhibitors (Refer to section 5) * Subjects with bowel obstruction * Subjects undergoing emergency surgery.